Johnson & Johnson (JNJ)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $680.19B
Last updated: Nov 17, 2026 at 4:43 PM ET
Johnson & Johnson (JNJ) Statistics
Johnson & Johnson (JNJ) has a market cap of $680.19B and an enterprise value of $707.93B. Its trailing P/E of 26.2x is above its 10-year median of 17.1x.
Total Valuation
Enterprise value is 4.08% above the market cap, as debt exceeds cash.
| Market Cap | $680.19B |
|---|---|
| Enterprise Value | $707.93B |
| Latest price (Nov 17, 2026) | $278.82 |
Key Dates
The next earnings report is set for Jan 26, 2027, after the close. The next ex-dividend date is Nov 24, 2026.
| Next Earnings Date | Jan 26, 2027, after the close |
|---|---|
| Last Earnings Date | Oct 13, 2026 |
| Next Ex-Dividend Date | Nov 24, 2026 |
| Next Payment Date | Dec 8, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 6.8x and 8.2x. Its year-end P/E ranged from 14.5x to 19.6x from 2016 to 2025.
| P/E Ratio | 26.2x |
|---|---|
| Forward P/E | 24.8x |
| P/S Ratio | 6.8x |
| Forward P/S | 6.7x |
| P/B Ratio | 8.2x |
| P/FCF Ratio | 33.6x |
| P/OCF Ratio | 26.0x |
| PEG Ratio | 2.6 |
Enterprise Valuation
Counting debt and cash, the company is valued at 27.0x EBITDA and 35.0x free cash flow.
| EV / Earnings | 44.0x |
|---|---|
| EV / Sales | 7.1x |
| EV / EBITDA | 27.0x |
| EV / EBIT | 39.7x |
| EV / FCF | 35.0x |
Price Statistics
The stock is up 43.96% over 52 weeks and trades 4.35% above its 50-day average.
| Beta (1Y) | -0.05 |
|---|---|
| 52-Week Change | +43.96% |
| 1-Month Change | +9.86% |
| 3-Month Change | +2.48% |
| 6-Month Change | +22.53% |
| 5-Year Change | +67.73% |
| 10-Year Change | +135.54% |
| Total Return (1Y) | +46.68% |
| Total Return (3Y CAGR) | +25.61% |
| Total Return (5Y CAGR) | +14.07% |
| Return vs SPY (1Y) | +29.47% |
| Max Drawdown (1Y) | -11.39% |
| Max Drawdown (3Y) | -14.45% |
| Sharpe Ratio (1Y) | 1.64 |
| Correlation with SPY (1Y) | -0.03 |
| 50-Day Average | $267.20 |
| 200-Day Average | $249.11 |
| 52-Week Range | $194.99 to $290.25 |
| RSI (14 Days) | 56.6 |
| Average Volume (20 Days) | 7.44M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.02x current liabilities, and total debt is 0.55x shareholder equity.
| Current Ratio | 1.02x |
|---|---|
| Quick Ratio | 0.74x |
| Debt / Equity | 0.55x |
| Debt / EBITDA | 1.72x |
| Debt / FCF | 2.23x |
| Interest Coverage | 18.14x |
Returns and Efficiency
Return on invested capital is 12.84% over the last 12 months, against a 5-year average of 15.38%.
| Return on Equity (ROE) | 19.74% |
|---|---|
| Return on Assets (ROA) | 8.15% |
| Return on Invested Capital (ROIC) | 12.84% |
| Return on Capital Employed (ROCE) | 12.57% |
| ROE (5Y Average) | 31.04% |
| ROA (5Y Average) | 12.66% |
| ROIC (5Y Average) | 15.38% |
| Asset Turnover | 0.51x |
| Inventory Turnover | 2.11x |
| Receivables Turnover | 5.22x |
| Cash Conversion Cycle | 138 days |
Taxes
Income tax took 9.26% of pretax income over the last 12 months.
| Income Tax (TTM) | $1.64B |
|---|---|
| Effective Tax Rate | 9.26% |
Scores
JNJ has an Altman Z-Score of 5.48, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 5.48 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $99.33B over the last 12 months is up 7.80% from the 12 months before.
| Revenue | $99.33B |
|---|---|
| Revenue Growth (YoY) | +7.80% |
| Gross Profit | $67.11B |
| Operating Income | $24.74B |
| Pretax Income | $17.74B |
| Net Income | $16.09B |
| EBITDA | $25.94B |
| EBIT | $17.85B |
| Reported EPS (TTM) | $10.65 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 41.30% of the $197.43B in total assets.
| Cash and Equivalents | $16.91B |
|---|---|
| Total Debt | $44.65B |
| Net Debt | $27.74B |
| Net Debt Per Share | $11.51 |
| Working Capital | $894.00M |
| Shareholder Equity | $81.53B |
| Book Value Per Share | $33.84 |
| Tangible Book Value | -$13.60B |
| Total Assets | $197.43B |
| Total Liabilities | $115.90B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $6.18B of capital spending, operating cash flow left $19.98B of free cash flow.
| Operating Cash Flow | $26.16B |
|---|---|
| Capital Expenditures | $6.18B |
| Free Cash Flow | $19.98B |
| FCF Per Share | $8.29 |
| Depreciation and Amortization | $8.09B |
| Dividends Paid | $12.72B |
| Share Repurchases | $7.88B |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 24.90%, against a 5-year average of 25.06%.
| Gross Margin | 67.56% |
|---|---|
| Operating Margin | 24.90% |
| Pretax Margin | 17.86% |
| Net Margin | 16.20% |
| EBITDA Margin | 26.11% |
| EBIT Margin | 17.97% |
| FCF Margin | 20.11% |
| Gross Margin (5Y Average) | 69.06% |
| Operating Margin (5Y Average) | 25.06% |
| Net Margin (5Y Average) | 26.90% |
Growth
Revenue grew 5.60% a year over 3 years, and EPS 2.06% a year.
| Revenue Growth (3Y CAGR) | +5.60% |
|---|---|
| Revenue Growth (5Y CAGR) | +2.67% |
| EPS Growth (3Y CAGR) | +2.06% |
| EPS Growth (5Y CAGR) | +6.11% |
| FCF Growth (3Y CAGR) | +4.65% |
| FCF Growth (5Y CAGR) | -0.49% |
| Operating Income Growth (3Y CAGR) | +8.21% |
| Book Value Per Share Growth (2Y CAGR) | +8.70% |
Dividends and Yields
JNJ pays out 48.64% of earnings as dividends.
| Dividend Per Share (Annual) | $5.36 |
|---|---|
| Dividend Yield | 1.92% |
| Payment Schedule | Quarterly |
| Dividend Growth (3Y CAGR) | +4.92% |
| Dividend Growth (5Y CAGR) | +5.25% |
| Payout Ratio | 48.64% |
| FCF Payout Ratio | 63.64% |
| Earnings Yield | 3.82% |
| FCF Yield | 2.97% |
| Buyback Yield | 1.17% |
| Shareholder Yield | 3.07% |
Stock Splits
The last split was a 2-for-1 forward split on Jun 13, 2001.
| Last Split Date | Jun 13, 2001 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 2:1 |
Peer Position
Against 9 similar companies, JNJ has the 3rd highest P/E.
P/E RatioPeer median 19.8x
P/S RatioPeer median 4.9x
ROICPeer median 13.95%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +6.13%
Dividend YieldPeer median 2.69%
| P/E Ratio | 26.2x vs 19.8x median |
|---|---|
| P/S Ratio | 6.8x vs 4.9x median |
| ROIC | 12.84% vs 13.95% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +7.80% vs +6.13% median |
| Dividend Yield | 1.92% vs 2.69% median |
Analyst Forecast
Consensus estimates put revenue growth at 6.96% and EPS growth at 3.74% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +6.96% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +3.74% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About JNJ
What is JNJ's market cap?
Johnson & Johnson has a market cap of $680.19B. Its enterprise value, which adds debt and subtracts cash, is $707.93B.
What is JNJ's P/E ratio?
Johnson & Johnson has a trailing P/E ratio of 26.2x and a forward P/E of 24.8x.
How many shares of JNJ are outstanding?
Johnson & Johnson has 2.41B shares outstanding. The count is up 0.05% from a year earlier.
Does JNJ pay a dividend?
Yes. Johnson & Johnson pays $5.36 a share a year, a dividend yield of 1.92%.
How much debt does JNJ have?
Johnson & Johnson has $44.65B of total debt and $16.91B of cash and equivalents, a net debt position of $27.74B.
JNJ pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts